Nikita Ermolaev

Vienna, 1090, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

A novel method to classify exercise response in patients with cardiac amyloidosis - The RoMa classification.

A novel method to classify exercise response in patients with cardiac amyloidosis - The RoMa classification.

Journal: European journal of preventive cardiology

Published: April 28, 2026

Fibroblast growth factor 23 is associated with cardiac disease severity in transthyretin amyloid cardiomyopathy.

Fibroblast growth factor 23 is associated with cardiac disease severity in transthyretin amyloid cardiomyopathy.

Journal: Scientific reports

Published: February 02, 2026

Prognostic impact of chronotropic incompetence in transthyretin cardiac amyloidosis: a multicentre study.

Prognostic impact of chronotropic incompetence in transthyretin cardiac amyloidosis: a multicentre study.

Journal: ESC heart failure

Published: February 01, 2026

Hereditary Transthyretin Amyloidosis in Austria: Clinical, Genetic, and Demographic Insights from a Nationwide Cohort.

Hereditary Transthyretin Amyloidosis in Austria: Clinical, Genetic, and Demographic Insights from a Nationwide Cohort.

Journal: Journal of clinical medicine

Published: January 26, 2026

CMR-derived skeletal muscle T1 time and extracellular volume as novel diagnostic markers for cardiac amyloidosis.

CMR-derived skeletal muscle T1 time and extracellular volume as novel diagnostic markers for cardiac amyloidosis.

Journal: European journal of clinical investigation

Published: December 22, 2025

Insights into the renin-angiotensin-aldosterone system in transthyretin amyloid cardiomyopathy.

Insights into the renin-angiotensin-aldosterone system in transthyretin amyloid cardiomyopathy.

Journal: European journal of heart failure

Published: December 01, 2025

Coronary Artery Disease in Cardiac Amyloidosis: Prevalence, Clinical Relevance, and Cardiac Magnetic Resonance Imaging Features.

Coronary Artery Disease in Cardiac Amyloidosis: Prevalence, Clinical Relevance, and Cardiac Magnetic Resonance Imaging Features.

Journal: Journal of clinical medicine

Published: October 24, 2025

Performance on the one-minute sit-to-stand test predicts long-term adverse outcomes in pulmonary hypertension.

Performance on the one-minute sit-to-stand test predicts long-term adverse outcomes in pulmonary hypertension.

Journal: Scientific reports

Published: September 26, 2025

Impact of disease-modifying therapy on [99mTc]Tc-DPD SPECT/CT markers in transthyretin cardiac amyloidosis enabled by artificial intelligence.

Impact of disease-modifying therapy on [99mTc]Tc-DPD SPECT/CT markers in transthyretin cardiac amyloidosis enabled by artificial intelligence.

Journal: European journal of nuclear medicine and molecular imaging

Published: September 05, 2025

Additive diagnostic value of thoracic SPECT/CT imaging in perugini grade 1 patients who underwent bone scintigraphy.

Additive diagnostic value of thoracic SPECT/CT imaging in perugini grade 1 patients who underwent bone scintigraphy.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 13, 2025

Applicability of phase 3 trial selection criteria to real-world transthyretin amyloid cardiomyopathy patients.

Applicability of phase 3 trial selection criteria to real-world transthyretin amyloid cardiomyopathy patients.

Journal: Scientific reports

Published: June 10, 2025

The 6-min walk test in transthyretin cardiac amyloidosis: prognostic utility put to the real-world test.

The 6-min walk test in transthyretin cardiac amyloidosis: prognostic utility put to the real-world test.

Journal: Frontiers in medicine

Published: June 02, 2025

Showing 1-12 of 26

Last Updated: 09/26/2026